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Abstract
Background: The Ebola virus is highly pathogenic and destructive to humans and other primates. The Ebola virus
encodes viral protein 40 (VP40), which is highly expressed and regulates the assembly and release of viral particles
in the host cell. Because VP40 plays a prominent role in the life cycle of the Ebola virus, it is considered as a key
target for antiviral treatment. However, there is currently no FDA-approved drug for treating Ebola virus infection,
resulting in an urgent need to develop effective antiviral inhibitors that display good safety profiles in a short duration.
Methods: This study aimed to screen the effective lead candidate against Ebola infection. First, the lead molecules
were filtered based on the docking score. Second, Lipinski rule of five and the other drug likeliness properties are
predicted to assess the safety profile of the lead candidates. Finally, molecular dynamics simulations was performed to
validate the lead compound.
Results: Our results revealed that emodin-8-beta-D-glucoside from the Traditional Chinese Medicine Database (TCMD)
represents an active lead candidate that targets the Ebola virus by inhibiting the activity of VP40, and displays good
pharmacokinetic properties.
Conclusion: This report will considerably assist in the development of the competitive and robust antiviral agents
against Ebola infection.
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Background
The Ebola virus is a virulent pathogen that causes
haemorrhagic fever in humans and animals, and that
leads to a fatality in nearly 90 % of cases within 7–11
days of infection [1]. The Ebola virus has proven to be
dangerous in many African countries, thereby contribu-
ting to its higher incidence of death [2]. Ebola carries a
negative-sense RNA genome containing seven genes
that encode seven different structural proteins: VP24,
VP30, VP35, VP40, a glycoprotein, a nucleoprotein and
a polymerase (L) [3]. In particular, the major matrix
protein VP40 appears to be highly expressed in Ebola
virus and plays a vital role in the budding of Ebola virus
from the plasma membrane [4].
Additionally, VP40 participates in host cell RNA me-
tabolism during the replication process [5, 6]. The
crystallographic structure of VP40-RNA reveals that
the R-134 and F-125 of VP40 mainly interact with
RNA [7]. These interactions play a crucial role in octa-
mer formation and promote the replication of the
Ebola virus. Mutational studies have shown that F-125
and R-134 mutations partially reduce RNA binding
and completely abolish RNA binding and octamer for-
mation, respectively [8]. It is clearlyevident from the
literature that the VP40-RNA binding mechanism is
crucial in the process of viral transcription at early
stages of infection [9]. These studies strongly suggest
that the binding of RNA to VP40 could be the critical
factors for the successful life cycle of the Ebola virus.
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Because VP40 plays a vital role in the Ebola virus life
cycle, it is considered as a potential target for the treat-
ment of Ebola virus infection. However, the pharmaco-
logical inhibition of VP40 has yet to be studied in
detail [6]. Meanwhile, no FDA-licensed drug is currently
available for the treatment of this lethal infection [10].
Thus, the screening of small molecules against Ebola virus
that target VP40 might shed light on the antiviral treat-
ment of this disease.
To address this issue, the Traditional Chinese Medicine
(TCM) Database (TCMD) [11] was used to identify novel,
potent lead compounds to combat Ebola infection. At
present, Computational approaches plays a vital role in
biological research. Virtual screening is one of the most
important promising techniques aids in dealing with a
large number of lead molecules and ranks them using mo-
lecular docking. As of today, many drugs are optimized
using computational approaches (Captopril, Dorzolamide,
Saquinavir, Zanamivir, Oseltamivir, Aliskiren, Boceprevir,
Nolatrexed, TMI-005, LY-517717, Rupintrivir and NVP-
AUY922) [12].
Previous studies have showed that the combination of
virtual screening with molecular docking and molecular
dynamics approaches can successfully identify novel
drug-like molecules for the treatment of infectious
diseases [13–18]. In this study, we also predicted the
oral toxicity (LD50) of the screened lead compounds to




The crystal structure of the matrix protein VP40 from the
Ebola virus was obtained from RCSB [19]. The corres-
ponding PDB code is 1H2C [7]. The three-dimensional
structures of the lead compounds were retrieved from the
TCMD. The three-dimensional structures of the target
proteins were energy-minimized using the GROMACS
package, version 4.6.3 [20, 21] adopting the GROMOS43a1
force field parameters before performing the docking ana-
lysis. Additional file 2: Figure S1 depicts the overall flow
chart of the present study.
Virtual screening
Virtual screening is an essential technique that is of
immense importance to the field of drug discovery. This
method is considered as an alternative approach to
experimental screening and has produced an increased
success rate in the drug discovery process [22, 23].
Because there is no FDA-approved drug available for
treating Ebola virus infection [24–26], we used iScreen
to apply a receptor-based virtual screening approach.
iScreen is a compact web server for TCM docking and
virtual screening [27]. iScreen utilizes the PLANTS
package, which is based on colony optimization, as a
docking algorithm [28]. This algorithm can efficiently rank
the potential lead candidates. The three-dimensional struc-
ture of VP40 was used as the input for identifying the
optimal lead compounds from TCMD. The RNA-VP40
binding site residues are used for virtual screening of lead
compounds.
Molecular docking analysis
The top ranked lead compounds were further evaluated
via molecular docking analysis using AutoDock 4.2.6
[29]. We have used different docking algorithms and re-
peated docking to increase the accuracy and reliability of
the docking result and to reduce the false positive out-
come. The AutoDock tools were used for the addition of
charges and polar hydrogens and the adjustment of
other parameters. Additionally, Autogrid was used to
generate grid maps and spacing [30]. Furthermore, the
Lamarckian genetic algorithm (LGA) was employed to
perform molecular docking. Each docking experiment
consisted of 10 different docking runs, which were set to
terminate after 250,000 energy evaluations. The docking
calculation included a population size of 150 and a
translational step of 0.2 Å, and the docking results were
ranked according to the binding free energy and the
frequency of the most probable binding site. Also, the
energetic contribution of screened lead compounds and
VP40 was analysed using PEARLS [31]. Furthermore,
the intermolecular interactions of the complexes were
analysed.
Intermolecular interaction analysis
In addition to the binding affinity of the molecules, their
inhibitory effect can be determined by analysing their in-
teractions with receptor molecules. In particular, hydrogen
bond interactions ensure the stability of drug-receptor
complexes. Thus, we use PDBsum [32] and Chimera [33]
to analyse the intermolecular interactions.
Molecular dynamics simulation
The structures of the docked complexes of VP40 with
the screened lead compounds were used as the starting
point for MD simulations using the GROMACS pack-
age, version 4.6.4 [20, 21] adopting the GROMOS43a1
force field parameters. The structures were solvated in a
cubic box with a size of 0.9 nm using periodic boundary
conditions and the SPC water model [34]. The topology
of the lead compounds was generated using the PRODRG
server [35]. Subsequently, energy minimization was per-
formed for both complex structures using the steepest
descent energy protocol. Furthermore, the systems were
equilibrated by performing a position-restrained dy-
namics simulation (NVT and NPT) at 300 K for 300 ps.
Then, the equilibrated structures were subjected to
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molecular dynamics simulations for 50,000psata con-
stant temperature of 300 K and pressure of 1 atm, and
the integration time step was set to 2 fs. The non-
bonded list was generated using an Atom-based thresh-
old of 8 Å. Long-range electrostatic interactions were
managed using the particle-mesh Ewald algorithm [36].
A 0.9 nm threshold was employed Lennard-Jones inter-
action. During the simulations, the lengths of all bonds
containing hydrogen atoms were constrained utilizing
the Lincs algorithm [37]; the trajectory snapshots were
stored for structural analysis every picosecond. The
RMSD and the hydrogen bonds were analysed using the
Gromacs utilities g_rms and g_hbond. Furthermore, the
MM-PBSA [38] was calculated to determine the binding
free energy between VP40 and the lead compounds.
ADME analysis and Drug likeliness analysis
Lipinski’s rule of five was used to testthe bioavailability
characteristics, such as the absorption, distribution, metab-
olism and elimination (ADME), of the lead compounds. In
the present study, these molecular properties and the drug-
likeness of the lead compounds were estimated using the
Molsoft program (http://molsoft.com/mprop/).
Prediction of toxicity risk and oral toxicity (LD50)
We predicted the preclinical oral toxicity (LD50) of the
lead compounds using the Osiris Property Explorer
(http://www.organic-chemistry.org/prog/peo/) and the
ProTox web server [39], respectively. The ProTox web
server prediction method is based on the analysis of
two-dimensional (2D) similarity to compounds displaying
known LD50 values and on the identification of over-
represented fragments in toxic compounds. The ProTox
server integrates toxicity class prediction using similarity-
and fragment-based methods with alerts for possible
toxicity targets, thus providing insight into the mecha-
nisms involved in the development of toxicity.
Results
Virtual screening and docking analysis
TCM plays an essential role in the field of medical diag-
nosis and treatment in East Asia. TCM emphasizes sys-
temic health using medicines originating from natural
herbs that exhibit few or no side effects. TCM has been
employed in China for thousands of years and remains a
very successful treatment modality in the medical field
[11]. The TCMD facilitates the virtual screening of TCM
compounds. Recently, increasing efforts have been de-
voted to studying the importance of TCM by isolating bio-
active compounds from the medicinal herbs employed in
TCM and by examining their activities. Therefore, we
employed the TCM database to screen for effective anti-
viral agents against Ebola virus infection. A total of 200
compounds from the TCM database were screened on the
basis of docking score, and the three top-ranked com-
pounds were sorted according to their docking scores. The
lists of top 15 compounds and their respective docking
scores were shown in Additional file 2: Table S1. The top 3
compounds are selected for the further analysis. The dock-
ing scores of compounds 1, 2 and 3 were -84.05, -82.62
and -82.44, respectively (Additional file 2: Table S2). Fur-
thermore, we performed docking analysis using AutoDock
to identify the binding affinity between the target and each
lead compound. To reduce the inconsistency of the results,
we performed repeated docking analyses. Information on
the binding site residues of VP40 was collected from the
available literature [7]. The docking results indicated that
the average binding affinities of compounds 1 and 2 were
higher than that of compound 3, as shown in Additional
file 2: Table S3. Thus, we performed further analyses on
these two lead compounds. The target protein structures
with 2 lead molecules in the docked conformation were
validated using PROCHECK to check for the steric clashes
occurred during docking experiment. The result showed
that the 100 % of residues fall in most favoured and
allowed regions in both complexes. This shows that both
the docked conformations free from steric clashes. Further-
more, the energetic contribution of lead compounds and
RNAwas analysed using PEARLS. This analysis confirmed
that the compound 1 and compound 2 exhibit better bind-
ing interactions with VP40 (Additional file 2: Table S4).
PDBsum [32] was used to visualize the interactions of the
complex structures. The interactions between VP40 and
the lead compounds are shown in Fig. 1. Compounds 1
and 2 maintained 6 and 3 hydrogen bond interactions,
respectively (Additional file 2: Table S5).
Furthermore, it has been clearly indicated in previous
studies that two conserved residues, F-125 and R-134,
are the most critical residues for RNA binding in the
Ebola virus and that R-134 plays a vital role in the repli-
cation of this virus [7]. Therefore, we analysed these key
interactions between VP40 and RNA using Chimera
[32]. The observed interaction between VP40 and RNA
indicated that R-134 of VP40 interacts with RNA via a
hydrogen bond and forms close contacts with T-123 and
F-125 (Fig. 2). Similarly, it is notable that two lead com-
pounds were able to establish a hydrogen bond inter-
action with R-134 and T-123 and were found to form a
close interaction with F-125 (Figs. 3 and 4), which has
been demonstrated to be crucial for the inhibition of
Ebola virus replication. Furthermore, the critical atoms
of lead compounds and RNA forming hydrogen bonds
with VP40 are depicted in (Additional file 2: Figures S2,
S3 and S4).
Molecular dynamics simulation
The docked complexes of the two lead molecules were
used for the molecular dynamics simulation. The potential
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energy plots obtained from the MD simulation showed
that both simulated interactions are stabilized throughout
the simulation process (Fig. 5). In addition, root mean
square deviation (RMSD) analysis showed that the VP40-
compound 1 interaction displayed an RMSD of ~0.45 at
50 ns into the simulation and that the VP40-compound
2 interaction displayed an RMSD of ~0.48 at the end of
the simulation. Both complexes displayed convergence
at ~30 ns into the simulation, indicating the stability of
both simulated interactions (Fig. 6). RMSD results indi-
cate that movement of both compounds are small and
thereby showing the strength of these compounds
within the binding pocket of the VP40. To further
validate the binding strength of these compounds and
Fig. 2 Chimera visualization of the key interacting residues between
RNA and VP40 (R-134, F-125 and T-123)
Fig. 3 Chimera visualization of the key interacting residues between































































































































































































Fig. 1 The interaction of compound 1 (a) and compound 2 (b) with VP40
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VP40. We plotted the distance between the lead com-
pounds and crucial binding residues (R-134 and F-125,
which illustrates the role in RNA binding and octamer
formation. Figures 7 and 8 show that both compounds
1 and 2 were situated a short distance from R-134 and
F-125, with minimal variation. This analysis indicated
that the both compounds 1 and 2 can competitively
bind to this target and may suppress the binding of
RNA to VP40 and also restrict the octamer formation
which is a key factor for viral replication. Also, it is well
known that hydrogen bond contribution of protein-
ligand determines the binding strength of the complex.
The hydrogen bonds reveal that both the compounds
interact with VP40 with a higher number of hydrogen
bonds. Figure 9 shows that compound 1 and 2 main-
tained 5-6 and 3-4 hydrogen bonds, respectively. These
analyses lead us to predict the consistent binding strength
of the compounds throughout the simulation time.
Although interaction analysis and hydrogen bond ana-
lysis helps in determining the binding of the compounds,
binding free energy from molecular dynamics calculation
is always crucial in determining the binding affinity of
the lead molecules in different time scale. Hence, we cal-
culated the binding free energy between VP40 and the
lead compounds using the molecular mechanics-
Poisson-Boltzmann surface area (MM-PBSA) approach.
Fig. 4 Chimera visualization of the key interacting residues between compound 2 and VP40 (R-134, F-125 and T-123)
Fig. 5 Potential energy variation for the VP40-compound 1 (black) and VP40-compound 2 (red) along the MD simulation
Karthick et al. Infectious Diseases of Poverty  (2016) 5:12 Page 5 of 10
As shown in Fig. 10, the average binding energy of com-
pounds 1 and 2 to VP40 ranged from~ -50 to -150 KJ/mol,
indicating a good binding affinity of compound 1 and 2 to
VP40. This analysis revealed that the targetable to maintain
the tight binding of the compounds during the whole simu-
lation time.
ADME and drug-likeness analysis
Based on the analysis described above, it was predicted
that compounds 1 and 2 are stable and display a high
binding affinity to the drug target. Molecular properties
such as the partition coefficient (logP), molecular
weight (MW), and the number of hydrogen bond ac-
ceptors and donors in a molecule are always considered
when predicting the bioavailability of the molecule [40].
These molecular properties were used to formulate
the “rule of five”21. This rule states that most mole-
cules displaying good membrane permeability exhibit
a molecular weight ≤500, a calculated octanol–water
partition coefficient, logP ≤5, hydrogen bond donor’s
≤5 and hydrogen bond acceptors ≤10 [41]. Therefore,
the molecular properties and bioactivity of these lead
compounds were predicted using the Molsoft program
(http://molsoft.com/mprop/) based on the Lipinski
rule of five, which states that an orally active com-
pound should have no more than one violation. The
results showed that both compounds 1 and 2 displayed
one violation, which is acceptable according to the
Lipinski rule of five (Additional file 2: Table S6) [42,
43]. Furthermore, drug-likeness is a key factor that
Fig. 6 Root mean square deviations correspond to VP40-compound 1 (black) and VP40-compound 2 (red) along the MD simulation
Fig. 7 Distance between R-134 of VP40 with compound 1 (black) and compound 2 (red) along the MD simulation
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determines the efficacy of the drug in terms of
favourable absorption, distribution, metabolism, excre-
tion and toxicological (ADMET) parameters. The
drug-likeness values of compounds 1 and 2 were 0.88
and 0.36, respectively, which indicated that 1 displays
higher druggability than compound 2.
Toxicity risks and oral toxicity (LD50) analysis
Drug discovery is a complicated procedure that requires
compounds to be highly bioavailable and safe to enter
the clinical phase. Toxicity and side effects are the major
issues that lead to the failure of a drug during its devel-
opment. Animal trials are currently the predominant
method used to determine the possible toxic effects of
drug candidates and cosmetics. In silico prediction
serves as an alternative approach for simplifying and ra-
tionalizing drug development at the preclinical stage,
thereby helping to minimize the cost, time, and animals
involved [44]. Therefore, we used the Osiris Property
Explorer to assess the toxicity risk of the screened lead
compounds. The analysis indicated that neither of these
lead compounds exerts any mutagenic, tumorigenic or
reproductive effects (Additional file 2: Table S7).
Furthermore, we used the Protoxweb server to calculate
the LD50 value of the screened lead compounds. Higher
the LD50 dose, lower the toxicity of the compound. The
Fig. 8 Distance between F-125 of VP40 with compound 1 (black) and compound 2 (red) along the MD simulation
Fig. 9 Hydrogen Bonds observed between the protein and ligand along the MD simulation. The symbol coding scheme is as follows: VP40-compound
1 (black) and VP40-compound 2 (red)
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predicted oral toxicity of compound 1 was 5000 mg/kg,
and the toxicity class is in the range of 5. These results in-
dicate that compound 1 displays a better safety profile
than compound 2 (Additional file 2: Table S7).
Discussion
Ebola infection has become a significant challenge to
human life, as Ebola has killed millions of people
thus far (http://www.cdc.gov/vhf/ebola/outbreaks/history/
distribution-map.html). Various efforts have been intro-
duced to develop effective vaccines against this disease.
However, no concrete report has demonstrated the
pharmacological inhibition of the Ebola virus. Because the
fatality rate of Ebola in humans is increasing each day,
there is an urgent need to develop potential drugs at a
faster pace. Thus, we adopted a computational approach
to support experimental biologists in developing an ef-
fective drug in a shorter duration. Virtual screening is a
modern technique that is used to prioritize active hits
based on their binding affinity to a target. Many successful
drug candidates have been developed against various
diseases using this technique. In particular, molecular
dynamics-based virtual screening is helpful for predicting
the quality of screened lead compounds. As TCM, the
most reliable source of medications, we employed the
TCMD for virtual screening.
In this report, we have computationally identified 2
TCM-based lead candidates, emodin-8-beta-D-glucoside
and tonkinochromane_G, as potential inhibitors of Ebola
infection. VP40 is a core target for antiviral agents be-
cause of its essential role in the replication of the Ebola
virus. VP40 binds to RNA, which forms an octameric
ring structure to promote the replication of the virus.
Interaction analysis showed that RNA forms a hydrogen
bond with R-134 and close interactions with F-125 and
T-123 (Fig. 2). R-134 and F-125 have previously been
demonstrated to be the key residues involved in RNA
binding [7]. In the present study, we found that both
lead compounds form a hydrogen bond interaction with
R-134 and interact with other key residues (Figs. 3 and 4)
that can negatively influence the binding of RNA to
VP40, potentially inhibiting the Ebola virus replication
process. In support of the docking analysis results, mo-
lecular dynamics simulations showed that these two lead
compounds are more stable and exhibit stronger binding
to VP40 due to forming a greater number of hydrogen
bonds. The MM-PBSA analysis also showed that these
lead compounds displayed a high binding affinity through-
out the simulation.
Finally, the molecular properties, carcinogenicity and
oral toxicity (LD50) parameters of these compounds in-
dicated that emodin-8-beta-D-glucoside might be a
more promising lead candidate than tonkinochroma-
ne_G for the future development of an effective anti-
viral agent against the Ebola virus. It is also to be noted
that emodin-8-O-beta-D-glucoside is extracted from
the herb Polygonum cuspidatum Sieb. etZucc, which is
used for the treatment against hepatitis and emodin-8-
O-beta-D-glucoside itself, demonstrated pharmacolo-
gical importance in neuro-protective effects against
cerebral ischemia-reperfused injury and glutamate-
induced neuronal damage [45]. While computations do
not provide a complete replacement for experimental
research, the relationship between computational and
experimental approaches is very crucial process to guide
the experimental biologist in screening and synthesize the
compound in more rational and rapid way [39]. Hence,
we hope that our computational findings will be crucial
for experimental biologists to develop antiviral agents very
quickly against the Ebola virus.
Fig. 10 Binding energy observed between the protein and ligand along the MD simulation. The symbol coding scheme is as follows: VP40-compound
1 (black) and VP40-compound 2 red)
Karthick et al. Infectious Diseases of Poverty  (2016) 5:12 Page 8 of 10
Conclusion
Emodin-8-beta-D-glucoside and tonkinochromane_G
are the lead candidates screened from the TCM database
that is predicted to have potential antiviral activity
against Ebola infection. Docking analysis revealed that
these lead compounds interact with R-134 and F-125,
which are the key residues for RNA binding. Further,
molecular dynamics simulation results also validated the
effective binding of these two compounds with the target.
Finally, predicted oral toxicity and other physicochemical
properties showed that emodin-8-beta-D-glucoside can be
safer and efficient lead candidate for the development of
antiviral therapeutics.
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